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Chronic Illness Panel, a group of more than two-million indi-
viduals who agreed to participate in surveys conducted by Harris
Interactive Service Bureau. Patients selected had a self-reported
diagnosis of hypertension and were receiving antihypertensive
medication. Questions assessed patients’ antihypertensive med-
ication class, blood pressure before and after initiation of the
medication, improvement in health status related to treatment,
and patients’ overall satisfaction with medication. RESULTS:
Using a web-based patient survey has several advantages. It pro-
vided a quick turn-around time as pilot testing and revising the
questionnaire were completed within a week, with full ﬁelding
of the survey accomplished in two-weeks. Because of the prior
consent, the study bypassed the sometimes lengthy approval
process by an Investigational Review Board. The direct entry of
the data by patients saved time and avoided errors from data
entry by a secondary person. The overall cost of the study was
lower than traditional mailing survey. A majority of missing data
occurred in questions related to patients’ recall of blood pressure
measurements. Data was mostly complete for questions with
subjective answers such as overall satisfaction. The limitations
of the web-based survey method included generalizability and
accuracy of recalled information. CONCLUSIONS: Using a
web-based survey is recommended for obtaining PRO in a timely
manner and at a low cost. However, the information should be
interpreted with care. The study subjects were from a select
group that may render selection bias. In addition, recalled infor-
mation seems difﬁcult to obtain and if reported, its accuracy may
be uncertain.
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OBJECTIVE: Because of the difﬁculty of early Venous Throm-
boembolism (VTE) diagnosis and the serious consequences of the
disease, prophylaxis is routinely indicated in medical at-risk
patients. This study examines the effect of VTE prophylaxis by
examining rate of secondary diagnosis of VTE in myocardial
infarction patients and its impact on overall costs of in-patient
care in order to optimize drug prophylaxis. METHODS: An
administrative database of 720,982 discharges containing ICD-
9-CM coding and other data from hospitals across the US was
analyzed. Study patients had a principal diagnosis of myocardial
infarction, and were prescribed heparin or enoxaparin. Associa-
tions between age, gender, length of stay (LOS), number of 
secondary diagnoses (NSD), drug, in-hospital deaths, overall
hospital costs, and incidence of VTE were studied using logistic
regression. RESULTS: From 8694 patients who met the inclu-
sion criteria, 35 patients (0.40%; two enoxaparin vs. 33 heparin)
showed a secondary diagnosis of VTE. Overall mean hospital
costs (p < 0.0001; OR = 2.685) were found to be signiﬁcantly
different between patients showing a secondary diagnosis of VTE
($30,617.4) and those who did not ($15,689.0). However, when
signiﬁcant clinical and demographic factors were controlled for
like LOS (p < 0.0001; OR = 1.053), in-hospital deaths (p =
0.0121; OR = 3.099), NSD (p < 0.0001; OR = 1.410), and age
(p = 0.0027; OR = 1.041), overall hospital costs were not found
to be signiﬁcantly different (p = 0.4459; OR = 1.255). In patients
who showed a secondary diagnosis of VTE, heparin prescribed
patients incurred higher mean overall hospital costs than enoxa-
parin patients; p < 0.0001 ($31,799.6 vs. $11,112.1), possibly
due to a longer LOS (11.4 days vs. 5.5 days). CONCLUSIONS:
The most cost-effective strategy in this analysis was VTE pre-
vention and enoxaparin was a cost-effective treatment choice.
Rational and adequate VTE prophylaxis needs to be addressed
along with further research on administrative database coding
and documentation issues in order to more fully explore the
application of these ﬁndings for a clinician.
PCV51
SHORT AND LONG-TERM COST-EFFECTIVENESS OF EARLY
AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY
WITH CLOPIDROGREL FOLLOWING PERCUTANEOUS
CORONARY INTERVENTION:A CANADIAN ECONOMIC
ANALYSIS
Kolm P1,Veledar E1, Forte L2,Amin M3, Bouin O4, Jackson J5,
Gabriel S4,Weintraub WS1
1Emory University, Atlanta, GA, USA; 2Sanoﬁ-Synthelabo, Markham,
ON, Canada; 3Bristol-Myers Squibb, St Laurent, QC, Canada;
4Sanoﬁ-Aventis, Bagneux, France; 5Bristol-Myers Squibb Company,
Princeton, NJ, USA
OBJECTIVES: Results from the pivotal Clopidogrel for the
Reduction of Events During Observation (CREDO) trial demon-
strated that one year of clopidogrel following a percutaneous
coronary intervention (PCI) signiﬁcantly reduced the absolute
combined risk of death, MI, or stroke by 3%. Utilizing 
Canadian Case Mix Group (CMG) costing, we sought to deter-
mine the incremental cost-effectiveness per event prevented over
one-year and estimate the incremental cost-effectiveness per life
year gained (LYG) for a clopidogrel + ASA strategy vs. ASA alone
before and after PCI. METHODS: Canadian health care
resource utilization costs were obtained from Case Mix Group
costing from the 2003 Health Funding and Costing Branch of
Alberta Health and Wellness Report. Cost-effectiveness was
expressed as the incremental cost per event prevented (ICERep)
or cost per life year gained (ICERlyg). Bootstrap methods were
used to estimate the joint distribution of cost and effectiveness
differences between the two arms and obtain 95% conﬁdence
intervals (CI). The Canadian costs of clopidogrel and aspirin
were C$2.40 per 75mg, and C$0.05 per tablet respectively. Life
expectancy in trial survivors was estimated from discounted
Framingham and Saskatchewan data. RESULTS: Total one-year
average cost per patient in clopidrogrel + ASA and ASA alone
arms were C$21,241 and C$20,786 respectively; a difference 
of C$455 (95% CI = -C$495 to C$1391). The ICERep was
C$15,040 with 59% of bootstrapped ICERs less than C$20,000
(87% less than C$50,000). The ICERlyg using Framingham esti-
mates was C$2980 with over 96% of bootstrapped ICERs less
than C$20,000 (98% less than C$50,000). The ICERlyg using
Saskatchewan estimates was C$2369 with over 97% of boot-
strapped ICERs less than C$20,000 (nearly 99% less than
C$50,000). CONCLUSION: Treatment with clopidogrel for 12-
months following PCI is highly cost-effective in the Canadian
health care system.
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Patients who survive an acute myocardial infarction (MI) are at
increased risk of subsequent major cardiovascular events and
